Drug discovery and the scale-up of newly developed manufacturing processes represent an exciting and dynamic field for academic scientists, startups, and small to large pharmaceutical companies. The scale-up to clinical batch sizes, in particular, poses challenges as lab-scale manufacturing expands to batch sizes in the multi-kg range, requiring further optimization of manufacturing processes. Due to the limited and often unknown safety profiles of new compounds, this scale-up is conducted in specialized facilities equipped with adequate contingency measures.

To ensure patient safety, a key issue in the manufacture of active pharmaceutical ingredients (APIs) in multi-purpose, multi-product manufacturing equipment is the adequate management of potential (cross-)contamination, especially when the product portfolio includes both developmental and commercial manufacturing processes.

 

 

Interested in reading the full resource?

Please fill out the form to unlock the rest of the content.

Latest Resources

Our team members share deep, scientific understanding and insights into their respective fields of expertise.

Want to hear more from Ardena?

Sign up to receive drug development insights, the latest on industry trends & Ardena news.

Stay up to date with our latest news and announcements.
Get deep, scientific understanding and insights into our key fields of expertise.
See the events we're attending and register for webinars we're hosting.